- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05443360
To Evaluate the Efficacy and Safety of Amorphous Calcium Carbonate in RA Patient With Osteopenia or Osteoporosis
A Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Amorphous Calcium Carbonate in Rheumatoid Arthritis Patients With Osteopenia or Osteoporosis
Study Overview
Status
Conditions
Detailed Description
This is a randomized, double-blind, active-controlled study to evaluate the efficacy and safety of amorphous calcium carbonate in rheumatoid arthritis patients with osteopenia or osteoporosis, compared to crystalized calcium carbonate.
A total of 180 subjects will be enrolled into this study. Eligible subjects will be randomized to receive amorphous calcium carbonate (ACC group) or crystalized calcium carbonate (CCC group) with 1:1 allocation. Randomization will be stratified by the use of biologics. The study product, 2 tablets (400mg calcium element), will be taken twice daily approximately 30 minutes after breakfast and dinner during 12-month treatment period. Additional 600 IU vitamin D3 will be also received with investigational product after breakfast.
The study will consist of 7 clinical visits. Subjects will come to the clinics at Visit 1 (screening visit), Visit 2 (randomization, regimen start), Visit 3 to 6 (follow-up visits), and Visit 7 (post-treatment follow-up visits) according to the pre-defined schedule.
The DXA score, and BTM (P1NP, CTX) from fasting serum samples, and FRAX score will be collected. The treatment-emergent adverse events for safety endpoints will be also recorded.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Der-Yuan Chen, Doctor
- Phone Number: 2031 886-4-22052121
- Email: dychen1957@gmail.com
Study Locations
-
-
-
Taichung, Taiwan, 404327
- Recruiting
- China Medical University Hospital
-
Contact:
- Der-Yuan Chen, Doctor
- Phone Number: 2031 886-4-22052121
- Email: dychen1957@gmail.com
-
Taipei, Taiwan, 112201
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Wei-Sheng Chen, Doctor
- Phone Number: 3366 886-2-28712121
- Email: weisheng0112@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women ≧45 years of age.
- Diagnosis of rheumatoid arthritis according to 2010 American College of Rheumatology Guideline (ACR Guideline), with severe osteopenia or osteoporosis.
- With a DAS28 (Disease Activity Score 28) score ranged from 2.6 to 5.1 at screening visit.
- With a documented DXA score ≦-2.0 at the lumbar spine or total hip and without compression fracture within the 3 months prior to screening visit.
- With a FRAX score at least medium risk (major osteoporotic fracture 10-19%, hip fracture 1-3%) at screening visit.
- Willingness to limit additional vitamin D3 intake to 600 IU per day during the study period.
- Ability to complete the entire procedure and to comply with study instructions.
- Will provide completed and signed written informed consents.
Exclusion Criteria:
- History of or current diseases that may interfere serum calcium, such as hypocalcemia, hypercalcemia, hyperparathyroidism, hypoparathyroidism, hyperthyroidism or hypothyroidism, or other metabolic bone disease, from any cause within 1 year prior to screening.
- Chronic kidney disease with receiving peritoneal dialysis or hemodialysis
- Known hypersensitivity to any component of the study product.
- Current treatment with any anti-osteoporotic drug (i.e. bisphosphonates, Denosumab (Prolia), teriparatide (Forteo), Romosozumab (Evenity), Raloxifene (Evista), etc.).
- Any previous or ongoing clinically significant illness that may interfere with the study conduct, as judged by the investigator.
- Participation in any other investigational study within 30 days prior to receiving study medication.
- Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: amorphous calcium carbonate (ACC group)
oral use, 2 ACC tablets (1000 mg / tablet, 200 mg calcium element / tablet) twice daily given after breakfast and dinner.
|
|
Active Comparator: crystalized calcium carbonate (CCC group)
oral use, 2 CCC tablets (1000 mg / tablet, 200 mg calcium element / tablet) twice daily given after breakfast and dinner.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change from baseline in bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA) in lumbar spine and total hip at Month 13
Time Frame: 12 months
|
The BMD and the corresponding change from baseline will be summarized with descriptive statistics and the 95% CI by study groups.
The difference in mean change from baseline in BMD between study groups will be analyzed by two sample t test.
Additionally, the intra-group difference will be analyzed by paired t test.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage change from baseline in bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA) in lumbar spine and total hip at Month 13
Time Frame: 12 months
|
The percentage change from baseline in BMD measured by DXA in lumbar spine and total hip at Month 13 will be summarized with descriptive statistics and the 95% CI by study groups.
The difference in percentage change from baseline in BMD between study groups will be analyzed by two sample t test.
|
12 months
|
Responder number and rate in bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA) in lumbar spine and total hip at Month 13
Time Frame: 12 months
|
The responder is defined as 20% reduction in DXA score from the baseline.
The responder will be presented as count and percentage in frequency table, and the 95% exact (Clopper-Pearson) CI will be provided as well by study group.
Fisher's exact test will be used for the comparison between study groups.
|
12 months
|
FRAX score (Fracture Risk Assessment Tool) change from baseline at Visit 1, 4, and 6
Time Frame: 12 months
|
The FRAX score and the corresponding change from baseline at Visit 1, 4, and 6 will be summarized with descriptive statistics and the 95% CI by study groups.
The difference in mean change from baseline in FRAX score between study groups will be analyzed by two sample t test.
Additionally, the intra-group difference will be analyzed by paired t test.
|
12 months
|
Bone turnover markers (BTM) change from baseline level 5.1 P1NP (total procollagen type 1 N-terminal propeptide) 5.2 CTX (C-terminal telopeptide of type 1 collagen)
Time Frame: 12 months
|
The bone turnover markers (BTM) includes P1NP (total procollagen type 1 N-terminal propeptide) and CTX (C-terminal telopeptide of type 1 collagen).
For the bone turnover markers (BTM), the descriptive summary of original values and the change from baseline will be provided by study groups.
Two sample t test will be used for the comparison of study groups in change from baseline be.
Additionally, the intra-group comparison will be analyzed by paired t test.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Der-Yuan Chen, Doctor, Rheumatology and Immunology Center
- Principal Investigator: Wei-Sheng Chen, Doctor, Division of Allergy, immunology and Rheumatology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Bone Diseases
- Arthritis
- Arthritis, Rheumatoid
- Osteoporosis
- Bone Diseases, Metabolic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antacids
- Calcium
- Calcium, Dietary
- Calcium Carbonate
Other Study ID Numbers
- CMUH111-REC2-014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on DENSITY™ (Amorphous calcium carbonate, ACC)
-
Amorphical Ltd.TerminatedDistal Radius FracturesIsrael
-
Amorphical Ltd.TerminatedHypoparathyroidismIsrael
-
Amorphical Ltd.TerminatedSolid Malignancies, With or Without Lung MetastasesIsrael
-
Amorphical Ltd.Terminated
-
Amorphical Ltd.WithdrawnCastrate Resistant Prostate Cancer With Bone MetastasisIsrael
-
Amorphical Ltd.Completed
-
Universal Integrated Corp.Taipei Medical UniversityCompletedOsteopenia | Bone Mineral Density | Calcium | Bone Turnover MarkerTaiwan
-
Unity Health TorontoCanadian Institutes of Health Research (CIHR)CompletedEnd-stage Renal DiseaseCanada
-
BayerCompleted
-
BayerRecruitingHealthy Volunteers | Heartburn | Indigestion | Stomach Acid Related Symptoms | Nocturnal Stomach Acid Related SymptomsUnited Kingdom